CN109071508A - 作为新型二价iap拮抗剂的苯并咪唑联吲哚化合物 - Google Patents

作为新型二价iap拮抗剂的苯并咪唑联吲哚化合物 Download PDF

Info

Publication number
CN109071508A
CN109071508A CN201780023651.4A CN201780023651A CN109071508A CN 109071508 A CN109071508 A CN 109071508A CN 201780023651 A CN201780023651 A CN 201780023651A CN 109071508 A CN109071508 A CN 109071508A
Authority
CN
China
Prior art keywords
fluoro
methyl
milliliters
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780023651.4A
Other languages
English (en)
Other versions
CN109071508B (zh
Inventor
孙飞
丁照中
蔡哲
钱文远
胡国平
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109071508A publication Critical patent/CN109071508A/zh
Application granted granted Critical
Publication of CN109071508B publication Critical patent/CN109071508B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了一类作为IAP拮抗剂的新型二价苯并咪唑联吲哚化合物,具体公开了式(I)所示化合物或其药学上可接受的盐。

Description

PCT国内申请,说明书已公开。

Claims (32)

  1. PCT国内申请,权利要求书已公开。
CN201780023651.4A 2016-04-27 2017-04-27 作为新型二价iap拮抗剂的苯并咪唑联吲哚化合物 Expired - Fee Related CN109071508B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016102710733 2016-04-27
CN201610271073 2016-04-27
PCT/CN2017/082227 WO2017186147A1 (zh) 2016-04-27 2017-04-27 作为新型二价iap拮抗剂的苯并咪唑联吲哚化合物

Publications (2)

Publication Number Publication Date
CN109071508A true CN109071508A (zh) 2018-12-21
CN109071508B CN109071508B (zh) 2021-09-03

Family

ID=60160707

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780023651.4A Expired - Fee Related CN109071508B (zh) 2016-04-27 2017-04-27 作为新型二价iap拮抗剂的苯并咪唑联吲哚化合物

Country Status (9)

Country Link
US (1) US10508103B2 (zh)
EP (1) EP3450430A4 (zh)
JP (1) JP2019514900A (zh)
KR (1) KR20180137518A (zh)
CN (1) CN109071508B (zh)
AU (1) AU2017258145A1 (zh)
CA (1) CA3022424A1 (zh)
RU (1) RU2018141411A (zh)
WO (1) WO2017186147A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
CN101516904A (zh) * 2006-07-24 2009-08-26 泰特拉洛吉克药业公司 二聚的iap拮抗剂
CN102471275A (zh) * 2009-07-02 2012-05-23 泰特拉洛吉克药业公司 Smac模拟物
US20140303090A1 (en) * 2013-04-08 2014-10-09 Tetralogic Pharmaceuticals Corporation Smac Mimetic Therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103083644B (zh) 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
CN101516904A (zh) * 2006-07-24 2009-08-26 泰特拉洛吉克药业公司 二聚的iap拮抗剂
CN102471275A (zh) * 2009-07-02 2012-05-23 泰特拉洛吉克药业公司 Smac模拟物
US20140303090A1 (en) * 2013-04-08 2014-10-09 Tetralogic Pharmaceuticals Corporation Smac Mimetic Therapy

Also Published As

Publication number Publication date
EP3450430A4 (en) 2019-12-11
RU2018141411A (ru) 2020-05-27
EP3450430A1 (en) 2019-03-06
WO2017186147A1 (zh) 2017-11-02
CN109071508B (zh) 2021-09-03
CA3022424A1 (en) 2017-11-02
US10508103B2 (en) 2019-12-17
KR20180137518A (ko) 2018-12-27
AU2017258145A1 (en) 2018-12-13
US20190135794A1 (en) 2019-05-09
JP2019514900A (ja) 2019-06-06

Similar Documents

Publication Publication Date Title
JP6650552B2 (ja) Ask1抑制剤としてのピリジン誘導体およびその製造方法ならびにその用途
CN106459009B (zh) 丙肝病毒抑制剂及其制药用途
ES2838573T3 (es) Derivados de benzamida ligados como inhibidores potentes de ROCK
CN113286794A (zh) Kras突变蛋白抑制剂
CN106459061A (zh) 作为hbv抑制剂的二氢嘧啶并环衍生物
CA2871471A1 (en) Dna-pk inhibitors
CN107531695A (zh) Jak抑制剂
KR101920472B1 (ko) 오렉신 수용체 길항제로서의 피페리딘 유도체
JP7123956B2 (ja) スピロ化合物およびその使用
EP3333157A1 (en) Vinyl compounds as fgfr and vegfr inhibitors
CN109575013A (zh) 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN105153164B (zh) 作为hbv抑制剂的二氢嘧啶并环衍生物
AU2018228555B2 (en) Azetidine derivative
CN112789087A (zh) Pad酶的苯并咪唑抑制剂
WO2023071998A1 (zh) 新型嘧啶或三嗪取代吡啶并杂环化合物
CN110418790B (zh) 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物
CN109661391B (zh) S1p1激动剂及其应用
CN109071508A (zh) 作为新型二价iap拮抗剂的苯并咪唑联吲哚化合物
CN111247161B (zh) 用作iap抑制剂的smac模拟物及其用途
CN107954997A (zh) 作为丙肝病毒抑制剂的联环化合物
AU2017359819B2 (en) FGFR4 inhibitor and preparation method and use thereof
CN110914243B (zh) 作为at2r受体拮抗剂的羧酸衍生物
CN110028508A (zh) 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
CN109803951A (zh) 作为cccDNA抑制剂的磺酰胺类化合物
CN105985333A (zh) 二氮杂-苯并荧蒽类化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210903